Indication assessment · §3
Hypoactive sexual desire and erectile dysfunction — trial records
Trial records in the Institute's register bearing on hypoactive sexual desire and erectile dysfunction.
§3Trials in this indication
16 trial records in the Institute's register bear on this indication, of which 3 are published trials.
Table 2. Trial records bearing on hypoactive sexual desire and erectile dysfunction.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| RECONNECT-301 | PT-141 (bremelanotide) | Phase 3 | Randomised, double-blind, placebo-controlled | 626 | 2019 |
| RECONNECT-302 | PT-141 (bremelanotide) | Phase 3 | Randomised, double-blind, placebo-controlled | 630 | 2019 |
| KISS-PH2-HSDD | Kisspeptin-10 | Phase 2 | Randomised crossover | 32 | 2017 |
| RECONNECT-301-BODY-COMPprogramme record | PT-141 (bremelanotide) | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2019 |
| RECONNECT-302-DDIprogramme record | PT-141 (bremelanotide) | Phase 1 | Randomised crossover | — | 2019 |
| KISS-PH2-HSDD-BIOMARKERprogramme record | Kisspeptin-10 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2017 |
| RECONNECT-301-REGIONAL-JPprogramme record | PT-141 (bremelanotide) | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2019 |
| RECONNECT-302-HEPATIC-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Phase 1 ascending dose | — | 2019 |
| KISS-PH2-HSDD-ADHERENCEprogramme record | Kisspeptin-10 | Phase 2 | Observational | — | 2017 |
| RECONNECT-301-REGIONAL-CNprogramme record | PT-141 (bremelanotide) | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2019 |
| RECONNECT-302-RENAL-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Phase 1 ascending dose | — | 2019 |
| KISS-PH2-HSDD-OLEprogramme record | Kisspeptin-10 | Phase 2 | Single-arm open-label | — | 2017 |
| RECONNECT-301-QOLprogramme record | PT-141 (bremelanotide) | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2019 |
| RECONNECT-302-PKprogramme record | PT-141 (bremelanotide) | Phase 1 | Phase 1 ascending dose | — | 2019 |
| KISS-PH2-HSDD-ELDERLYprogramme record | Kisspeptin-10 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2017 |
| RECONNECT-301-ADHERENCEprogramme record | PT-141 (bremelanotide) | Phase 3 | Observational | — | 2019 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-25/3 · https://compoundevidence.com/indications/sexual-dysfunction/trials/ · retrieved 30 July 2026